Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643487 | PMC |
| http://dx.doi.org/10.1016/j.jceh.2023.05.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Course of COVID-19 Infection in Patients With Chronic Hepatitis Delta.
J Viral Hepat
January 2025
Department of Gastroenterology and Hepatology, Koç University Medical School, Istanbul, Turkey.
In coronavirus disease 2019 (COVID-19), older age and co-morbidities are associated with mortality. Among liver disease aetiologies alcoholic liver disease was associated with mortality. Chronic hepatitis delta (CHD) had not been studied.
View Article and Find Full Text PDFThe Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma.
Cancers (Basel)
November 2024
Clínica Universitária de Gastrenterologia, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.
Hepatitis delta virus (HDV) infection requires the presence of hepatitis B virus (HBV), and chronic HBV-HDV coinfection is considered the most severe form of viral hepatitis. When compared with HBV mono-infection, HBV-HDV coinfection is associated with higher rates of liver cirrhosis and hepatocellular carcinoma (HCC). In this review, we aim to elucidate the complex relationship between HDV infection and the development of HCC.
View Article and Find Full Text PDFAn updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance.
Metabolism
January 2025
Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Torino, Italy. Electronic address:
Article Synopsis
- Hepatocellular carcinoma (HCC) is increasingly linked to Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), with up to 38% of cases potentially related to this condition.
- The rise of metabolic syndrome, viewed as a "silent pandemic," highlights the need to understand the connection between insulin resistance, inflammation, and complications like HCC.
- The review will explore new findings in immunology, liver damage from gut issues, and the relationship with other cancers, while also discussing strategies for monitoring HCC risk and the impact of new treatments on liver disease.
Retrospective cohort evaluation study in terms of cardiovascular and metabolic diseases in chronic hepatitis B patients.
Front Endocrinol (Lausanne)
October 2024
Department of Gastroenterology, İstanbul Medipol University Sefakoy Health Practice Research Center, Istanbul, Türkiye.
Background: Chronic hepatitis B (CHB) and nucleotide analogues [entecavir (ETV) and tenofovir disoproxil fumarate (TDF)] used in its treatment have been shown to affect metabolic parameters in many studies. In this study, we aimed to investigate the effects of metabolic events associated with CHB and nucleotide analogues (NAs) used in CHB treatment on ischemic heart diseases (IHD) and cardiovascular diseases (CVD).
Methods: This retrospective study was conducted between June 2022 and January 2024 with a total of 241 patients diagnosed with non-cirrhotic CHB in the gastroenterology outpatient clinic, 96 of whom did not receive hepatitis B treatment, 110 of whom received TDF, and 35 of whom received ETV treatment.
Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients.
Adv Ther
November 2024
Loma Linda University, Loma Linda, CA, USA.
Introduction: Non-alcoholic steatohepatitis (NASH) may progress to more advanced liver disease. This study aimed to characterize NASH progression and mortality in the Medicare population.
Methods: Patients with NASH in 100% Medicare fee-for-service claims accrued from 2015-2021 who were ≥ 66 years old at index diagnosis, continuously enrolled for ≥ 12 months prior to and ≥ 6 months following index (unless death), and had no evidence of other causes of liver disease were included.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!